The epidermal growth factor receptor (EGFR) is a primary contributor to glioblastoma (GBM)
initiation and progression. Here, we examine how EGFR and key downstream signaling …

Eighty-five percent of patients with lung cancer present with Non-small Cell Lung Cancer
(NSCLC). Targeted therapy approaches are promising treatments for lung cancer. However …

The extent to which ligand occupancy and dimerization contribute to erbB1 signaling is
controversial. To examine this, we used two-color quantum-dot tracking for visualization of …

Although the ERK pathway has a central role in the response of cells to growth factors, its
regulatory structure and dynamics are incompletely understood. To investigate ERK …

Deregulation of ErbB signaling plays a key role in the progression of multiple human
cancers. To help understand ErbB signaling quantitatively, in this work we combine …

Resistance to targeted cancer therapies such as trastuzumab is a frequent clinical problem
not solely because of insufficient expression of HER2 receptor but also because of the …

Often considered to be a “dead” kinase, erbB3 is implicated in escape from erbB-targeted
cancer therapies. Here, heregulin stimulation is shown to markedly upregulate kinase …

Epilepsy, a prevalent neurological disorder characterized by disrupted brain activity, affects
over 70 million individuals worldwide, as reported by the World Health Organization (WHO) …

Receptors constitute the interface of cells to their external environment. These molecules
bind specific ligands involved in multiple processes, such as signal transduction and nutrient …

The wealth of morphological, histological, and molecular data from human cancers available
to pathologists means that pathology is poised to become a truly quantitative systems …